Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.

Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62

Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J (2016) 1.38

Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail (2014) 1.07

Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail (2009) 1.04

'It could be worse ... lot's worse!' Why health-related quality of life is better in older compared with younger individuals with heart failure. Age Ageing (2013) 1.02

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98

Poor sleep and impaired self-care: towards a comprehensive model linking sleep, cognition, and heart failure outcomes. Eur J Cardiovasc Nurs (2009) 0.92

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol (2011) 0.90

Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail (2013) 0.87

Health-related quality of life in elderly patients hospitalized with chronic heart failure. Clin Interv Aging (2013) 0.87

Prevalence and characteristics of multiple psychiatric disorders in cardiac rehabilitation patients. J Cardiopulm Rehabil Prev (2009) 0.85

Type D personality is a predictor of poor emotional quality of life in primary care heart failure patients independent of depressive symptoms and New York Heart Association functional class. J Behav Med (2010) 0.84

The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction. Curr Heart Fail Rep (2016) 0.84

Sleep and health-related quality of life in heart failure. Congest Heart Fail (2009) 0.81

Cognitive Function Does Not Impact Self-reported Health-Related Quality of Life in Heart Failure Patients. J Cardiovasc Nurs (2016) 0.77

Comparison of health-related quality of life between American and Taiwanese heart failure patients. J Transcult Nurs (2010) 0.77

Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations. J Cardiovasc Transl Res (2017) 0.76

Quality of Life for Saudi Patients With Heart Failure: A Cross-Sectional Correlational Study. Glob J Health Sci (2015) 0.76

Gender-Specific Physical Symptom Biology in Heart Failure. J Cardiovasc Nurs (2015) 0.75

Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. JACC Heart Fail (2016) 0.75

Symptom-Hemodynamic Mismatch and Heart Failure Event Risk. J Cardiovasc Nurs (2015) 0.75

Symptom burden in heart failure: assessment, impact on outcomes, and management. Heart Fail Rev (2017) 0.75

Global Public Health Burden of Heart Failure. Card Fail Rev (2017) 0.75

Evaluation of Quality of Life in Patients with and without Heart Failure in Primary Care. Arq Bras Cardiol (2017) 0.75

Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations. J Cardiovasc Transl Res (2017) 0.75

Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42

A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30

Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46

Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J (2008) 12.32

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88

Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14

Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62

C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation (2006) 9.44

Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12

AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation (2004) 7.72

Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail (2008) 6.80

The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25

Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22